SYK and neoplasm: The present study was undertaken in order to evaluate the effect Na-Bu, 2,4-Diamino-5-oxo-pyrimidine hydrochloride (CDKi), a broad spectrum kinase inhibitor and BAY 61-3606 (Syk inhibitor) on the survival of VS tumour tissues in vitro  and their possible effects on cell survival/death and levels of a few key proteins in the treated cells as compared to the untreated cells.